Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$42.3B
sum of reported positions
Reported positions
227
Changes vs prior quarter
244
33 new · 48 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 284 measured positions in 8 quarters, the typical new or larger position finished −1.8 pts against the S&P 500 and 47% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $28.2B | $42.3B |
| Positions | 242 | 227 |
| Biggest line | — | Apple 7% |
| 5.56M |
| $1.99B |
| 4.7% |
| 2.84M | $1.65B | 3.9% |
| 1.22M | $1.41B | 3.3% |
| 493K | $1.12B | 2.7% |
| 2.36M | $1.02B | 2.4% |
| 984K | $950M | 2.2% |
| 6.71M | $937M | 2.2% |
| 2.93M | $883M | 2.1% |
| 2.13M | $805M | 1.9% |
| 3.06M | $781M | 1.8% |
| 1.92M | $685M | 1.6% |
| 1.57M | $617M | 1.5% |
| 1.73M | $611M | 1.4% |
| 1.67M | $570M | 1.3% |
| 939K | $529M | 1.3% |
| 793K | $507M | 1.2% |
| 1.56M | $451M | 1.1% |
| 2.53M | $430M | 1.0% |
| 1.15M | $418M | 1.0% |
| 538K | $411M | 1.0% |
| 2.49M | $404M | 1.0% |
| 1.97M | $368M | 0.9% |
Affiliated Managers Group (AMG)
87K → 85K shares (−2%)
Dyne Therapeutics (DYN)
1.36M → 1.29M shares (−5%)
Stoke Therapeutics (STOK)
1.13M → 834K shares (−26%)
Bioage Labs (BIOA)
1.13M → 1.07M shares (−5%)
Cigna (CI)
116K → 88K shares (−24%)
Littelfuse (LFUS)
59K → 52K shares (−11%)
Guardant Health (GH)
173K → 159K shares (−8%)
Kymera Therapeutics (KYMR)
215K → 204K shares (−5%)
Bank of America (BAC)
375K → 350K shares (−7%)
Monopar Therapeutics (MNPR)
227K → 214K shares (−5%)
Applied Materials (AMAT)
37K → 27K shares (−26%)
SharkNinja (SN)
131K → 115K shares (−12%)
Royal Bank of Canada (RY)
98K → 89K shares (−8%)
Mastercard (MA)
34K → 25K shares (−27%)
Cenovus Energy (CVE)
656K → 433K shares (−34%)
Qualcomm (QCOM)
82K → 55K shares (−33%)
Photronics, Inc. (PLAB)
513K → 299K shares (−42%)
Relmada Therapeutics (RLMD)
1.41M → 1.34M shares (−5%)
Nlight (LASR)
320K → 125K shares (−61%)
Amdocs (DOX)
160K → 137K shares (−14%)
MasterBrand, Inc. (MBC)
744K → 560K shares (−25%)
Builders Firstsource (BLDR)
65K → 53K shares (−18%)
Inventiva (IVA)
2.13M → 1.07M shares (−50%)
Open Text (OTEX)
251K → 175K shares (−30%)
Cg Oncology (CGON)
704K → 43K shares (−94%)
